Hepatitis B associated hepatocellular carcinoma
Conditions
Interventions
Have undergone resection or radical radiofrequency ablation of liver cancer (using NAs):none
Have undergone resection or radiofrequency ablation of liver cancer (using NAs and Peg-IFN-a-2b):none
Patients who did not undergo radical liver cancer resection or radiofrequency ablation (using NAs):none
Patients who were not treated with radical liver cancer resection or radiofrequency ablation (using NAs and Peg-IFN-a-2b):none
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Voluntary entry, able to understand and sign informed consent; (2) HBsAg positive during screening; (3) HCC patients who have been confirmed by histopathology according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 edition) issued by the National Health and Family Planning Commission, or/and who have been diagnosed with HCC according to the imaging criteria of the American Association for the Study of Liver Diseases (AASLD); (4) Child-Pugh grade A before treatment; (5) Platelet =70×109/l; (6) Age =65 years old; (7) The subject and the subject's spouse are not pregnant during the treatment.
Exclusion criteria
Exclusion criteria: (1) Liver cancer patients with intrahepatic cholangiocarcinoma (ICC) or HCC-ICC mixed type confirmed by pathological examination. Metastatic liver cancer. (2) Patients with a history of mental illness (such as schizophrenia or severe depression), uncontrolled epilepsy, uncontrolled autoimmune diseases, chronic diseases such as severe cardiovascular and cerebrovascular diseases, or other primary malignant tumors. (3) Patients with other hepatitis virus infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival with different treatment regimens; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver imaging changes under different treatment regimens;Serum HBV DNA was treated with different treatment regimens;Serum HBsAg was treated with different treatment regimens;Overall survival with different treatment regimens;Serum HBsAb was treated with different treatment regimens;Serum AFP was treated with different treatment regimens; | — |
Countries
China
Contacts
Public ContactLu Xiaobo
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed